25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AVTX (Avalo Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Avalo Therapeutics Inc together

I guess you are interested in Avalo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Avalo Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Avalo Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Avalo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Avalo Therapeutics Inc

I send you an email if I find something interesting about Avalo Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Avalo Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Avalo Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.1%

What is your share worth?

Current worth
$11.32
Expected worth in 1 year
$31.98
How sure are you?
51.3%

+ What do you gain per year?

Total Gains per Share
$20.66
Return On Investment
432.2%

For what price can you sell your share?

Current Price per Share
$4.78
Expected price per share
$3.39 - $5.99
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Avalo Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$4.78
Intrinsic Value Per Share
$-30.39 - $11.58
Total Value Per Share
$-19.06 - $22.91

2.2. Growth of Avalo Therapeutics Inc (5 min.)




Is Avalo Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$122.6m-$21.5m$90.1m131.3%

How much money is Avalo Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money$18.2m-$35.7m$53.9m295.7%
Net Profit Margin-2,288.5%-1,230.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Avalo Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#314 / 872

Most Revenue
#550 / 872

Most Profit
#67 / 872

Most Efficient
#765 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Avalo Therapeutics Inc?

Welcome investor! Avalo Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Avalo Therapeutics Inc.

First you should know what it really means to hold a share of Avalo Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Avalo Therapeutics Inc is $4.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Avalo Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Avalo Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $11.32. Based on the TTM, the Book Value Change Per Share is $5.17 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Avalo Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.21-25.4%1.6935.3%-3.30-69.0%-0.75-15.7%-1.14-23.8%-0.79-16.5%
Usd Book Value Change Per Share-0.96-20.1%5.17108.1%-2.19-45.8%0.8918.7%0.459.4%0.367.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.96-20.1%5.17108.1%-2.19-45.8%0.8918.7%0.459.4%0.367.6%
Usd Price Per Share8.01-9.35-7.83-6.61-4.89-3.93-
Price to Earnings Ratio-1.65--0.19--0.92--0.32--0.34--0.59-
Price-to-Total Gains Ratio-8.33--0.45--5.23--1.34--0.93-6.45-
Price to Book Ratio0.71--14.14-2.67--6.04--3.25-1.96-
Price-to-Total Gains Ratio-8.33--0.45--5.23--1.34--0.93-6.45-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.78
Number of shares209
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share5.170.45
Usd Total Gains Per Share5.170.45
Gains per Quarter (209 shares)1,079.4993.64
Gains per Year (209 shares)4,317.97374.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10431843080375365
20863686260749740
301295412944011241115
401727217262014981490
502159021580018731865
602590825898022472240
703022630216026222615
803454434534029972990
903886238852033713365
1004318043170037463740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%3.017.00.015.0%5.034.00.012.8%5.041.00.010.9%
Book Value Change Per Share3.01.00.075.0%6.06.00.050.0%9.011.00.045.0%20.019.00.051.3%21.022.03.045.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.037.05.1%2.00.044.04.3%
Total Gains per Share3.01.00.075.0%6.06.00.050.0%9.011.00.045.0%20.019.00.051.3%21.022.03.045.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Avalo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9625.165-119%-2.189+128%0.895-208%0.448-315%0.360-367%
Book Value Per Share--11.3246.340+79%-1.987+118%1.257+801%1.854+511%1.443+685%
Current Ratio--22.60711.244+101%1.194+1793%4.448+408%3.726+507%2.729+728%
Debt To Asset Ratio--0.1150.510-77%1.064-89%0.919-88%0.771-85%0.886-87%
Debt To Equity Ratio--0.1300.984-87%0.717-82%0.567-77%1.198-89%2.236-94%
Dividend Per Share----0%-0%-0%-0%0.002-100%
Enterprise Value--195867076.000154622879.000+27%47246828.710+315%68073145.800+188%52916826.416+270%38923592.613+403%
Eps---1.2141.686-172%-3.299+172%-0.753-38%-1.139-6%-0.788-35%
Ev To Ebitda Ratio---3.369-3.069-9%-1.919-43%-1.592-53%-1.153-66%-1.227-64%
Free Cash Flow Per Share---0.873-1.208+38%-0.619-29%-0.771-12%-1.026+17%-0.657-25%
Free Cash Flow To Equity Per Share---0.8730.345-353%2.149-141%0.663-232%0.424-306%0.214-508%
Gross Profit Margin--1.0011.0060%1.001+0%1.0020%1.019-2%0.970+3%
Intrinsic Value_10Y_max--11.584----------
Intrinsic Value_10Y_min---30.389----------
Intrinsic Value_1Y_max---2.083----------
Intrinsic Value_1Y_min---3.097----------
Intrinsic Value_3Y_max---3.786----------
Intrinsic Value_3Y_min---9.316----------
Intrinsic Value_5Y_max---2.509----------
Intrinsic Value_5Y_min---15.499----------
Market Cap51755928.000-68%86729076.000101265129.000-14%84796078.710+2%71593895.800+21%52922980.866+64%42537003.966+104%
Net Profit Margin----22.8850%-12.3000%-15.4170%-20.3400%-12.2250%
Operating Margin----30.2450%-10.3680%-16.8710%-20.7960%-12.1220%
Operating Ratio---30.745-100%9.145-100%16.927-100%21.229-100%13.290-100%
Pb Ratio0.422-68%0.707-14.145+2100%2.674-74%-6.045+955%-3.247+559%1.960-64%
Pe Ratio-0.984+40%-1.649-0.190-88%-0.920-44%-0.322-80%-0.338-79%-0.588-64%
Price Per Share4.780-68%8.0109.353-14%7.831+2%6.612+21%4.888+64%3.929+104%
Price To Free Cash Flow Ratio-1.368+40%-2.293-1.983-13%-4.513+97%-2.366+3%-1.594-30%-4.072+78%
Price To Total Gains Ratio-4.968+40%-8.326-0.453-95%-5.231-37%-1.340-84%-0.929-89%6.446-229%
Quick Ratio--22.27011.006+102%1.095+1934%4.308+417%3.591+520%2.604+755%
Return On Assets---0.0950.203-147%-0.472+397%-0.163+72%-0.213+125%-0.203+114%
Return On Equity---0.1070.180-160%-0.369+244%-0.063-41%-0.423+294%-0.814+659%
Total Gains Per Share---0.9625.165-119%-2.189+128%0.895-208%0.448-315%0.362-366%
Usd Book Value--122615000.00068643000.000+79%-21513750.000+118%13613000.000+801%20076989.050+511%15624747.821+685%
Usd Book Value Change Per Share---0.9625.165-119%-2.189+128%0.895-208%0.448-315%0.360-367%
Usd Book Value Per Share--11.3246.340+79%-1.987+118%1.257+801%1.854+511%1.443+685%
Usd Dividend Per Share----0%-0%-0%-0%0.002-100%
Usd Enterprise Value--195867076.000154622879.000+27%47246828.710+315%68073145.800+188%52916826.416+270%38923592.613+403%
Usd Eps---1.2141.686-172%-3.299+172%-0.753-38%-1.139-6%-0.788-35%
Usd Free Cash Flow---9457000.000-13077750.000+38%-6707500.000-29%-8348833.333-12%-11106014.250+17%-7115262.436-25%
Usd Free Cash Flow Per Share---0.873-1.208+38%-0.619-29%-0.771-12%-1.026+17%-0.657-25%
Usd Free Cash Flow To Equity Per Share---0.8730.345-353%2.149-141%0.663-232%0.424-306%0.214-508%
Usd Market Cap51755928.000-68%86729076.000101265129.000-14%84796078.710+2%71593895.800+21%52922980.866+64%42537003.966+104%
Usd Price Per Share4.780-68%8.0109.353-14%7.831+2%6.612+21%4.888+64%3.929+104%
Usd Profit---13149000.00018253000.000-172%-35719750.000+172%-8285750.000-37%-12411933.300-6%-8570343.564-35%
Usd Revenue---110250.000-100%362500.000-100%1603666.667-100%1487937.500-100%2162137.179-100%
Usd Total Gains Per Share---0.9625.165-119%-2.189+128%0.895-208%0.448-315%0.362-366%
 EOD+3 -5MRQTTM+16 -19YOY+25 -103Y+15 -205Y+20 -1510Y+18 -19

3.3 Fundamental Score

Let's check the fundamental score of Avalo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.984
Price to Book Ratio (EOD)Between0-10.422
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than122.270
Current Ratio (MRQ)Greater than122.607
Debt to Asset Ratio (MRQ)Less than10.115
Debt to Equity Ratio (MRQ)Less than10.130
Return on Equity (MRQ)Greater than0.15-0.107
Return on Assets (MRQ)Greater than0.05-0.095
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Avalo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.365
Ma 20Greater thanMa 504.812
Ma 50Greater thanMa 1004.462
Ma 100Greater thanMa 2005.566
OpenGreater thanClose4.880
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Fundamental data was last updated by Penke on 2025-07-11 11:31:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Avalo Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Avalo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,288.5%+2,288.5%
TTM-2,288.5%YOY-1,230.0%-1,058.5%
TTM-2,288.5%5Y-2,034.0%-254.5%
5Y-2,034.0%10Y-1,222.5%-811.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM-2,288.5%-140.9%-2,147.6%
YOY-1,230.0%-197.6%-1,032.4%
3Y-1,541.7%-248.5%-1,293.2%
5Y-2,034.0%-343.4%-1,690.6%
10Y-1,222.5%-496.2%-726.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Avalo Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • -9.5% Return on Assets means thatΒ Avalo Therapeutics Inc generatedΒ $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Avalo Therapeutics Inc:

  • The MRQ is -9.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 20.3%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ-9.5%TTM20.3%-29.8%
TTM20.3%YOY-47.2%+67.5%
TTM20.3%5Y-21.3%+41.7%
5Y-21.3%10Y-20.3%-1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.5%-11.6%+2.1%
TTM20.3%-11.6%+31.9%
YOY-47.2%-11.4%-35.8%
3Y-16.3%-11.8%-4.5%
5Y-21.3%-12.0%-9.3%
10Y-20.3%-13.7%-6.6%
4.3.1.3. Return on Equity

Shows how efficient Avalo Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • -10.7% Return on Equity means Avalo Therapeutics Inc generated $-0.11Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Avalo Therapeutics Inc:

  • The MRQ is -10.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 18.0%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ-10.7%TTM18.0%-28.7%
TTM18.0%YOY-36.9%+54.9%
TTM18.0%5Y-42.3%+60.3%
5Y-42.3%10Y-81.4%+39.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.7%-13.5%+2.8%
TTM18.0%-14.9%+32.9%
YOY-36.9%-14.6%-22.3%
3Y-6.3%-16.8%+10.5%
5Y-42.3%-17.5%-24.8%
10Y-81.4%-19.9%-61.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Avalo Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Avalo Therapeutics Inc is operatingΒ .

  • Measures how much profit Avalo Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Avalo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3,024.5%+3,024.5%
TTM-3,024.5%YOY-1,036.8%-1,987.7%
TTM-3,024.5%5Y-2,079.6%-944.9%
5Y-2,079.6%10Y-1,212.2%-867.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--232.5%+232.5%
TTM-3,024.5%-250.5%-2,774.0%
YOY-1,036.8%-209.2%-827.6%
3Y-1,687.1%-234.1%-1,453.0%
5Y-2,079.6%-346.1%-1,733.5%
10Y-1,212.2%-477.5%-734.7%
4.3.2.2. Operating Ratio

Measures how efficient Avalo Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM30.745-30.745
TTM30.745YOY9.145+21.600
TTM30.7455Y21.229+9.516
5Y21.22910Y13.290+7.939
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM30.7452.694+28.051
YOY9.1453.096+6.049
3Y16.9273.652+13.275
5Y21.2294.745+16.484
10Y13.2906.614+6.676
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Avalo Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Avalo Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 22.61Β means the company has $22.61 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 22.607. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.244. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ22.607TTM11.244+11.363
TTM11.244YOY1.194+10.050
TTM11.2445Y3.726+7.518
5Y3.72610Y2.729+0.997
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.6073.661+18.946
TTM11.2443.846+7.398
YOY1.1944.140-2.946
3Y4.4484.688-0.240
5Y3.7265.746-2.020
10Y2.7296.147-3.418
4.4.3.2. Quick Ratio

Measures if Avalo Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 22.27Β means the company can pay off $22.27 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 22.270. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.006. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ22.270TTM11.006+11.264
TTM11.006YOY1.095+9.911
TTM11.0065Y3.591+7.415
5Y3.59110Y2.604+0.987
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.2702.848+19.422
TTM11.0063.169+7.837
YOY1.0953.786-2.691
3Y4.3084.311-0.003
5Y3.5915.703-2.112
10Y2.6046.368-3.764
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Avalo Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Avalo Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Avalo Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11Β means that Avalo Therapeutics Inc assets areΒ financed with 11.5% credit (debt) and the remaining percentage (100% - 11.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 0.115. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.510. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.115TTM0.510-0.395
TTM0.510YOY1.064-0.554
TTM0.5105Y0.771-0.261
5Y0.77110Y0.886-0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1150.329-0.214
TTM0.5100.349+0.161
YOY1.0640.331+0.733
3Y0.9190.340+0.579
5Y0.7710.349+0.422
10Y0.8860.379+0.507
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Avalo Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 13.0% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Avalo Therapeutics Inc:

  • The MRQ is 0.130. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.984. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.130TTM0.984-0.854
TTM0.984YOY0.717+0.267
TTM0.9845Y1.198-0.215
5Y1.19810Y2.236-1.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1300.379-0.249
TTM0.9840.437+0.547
YOY0.7170.414+0.303
3Y0.5670.450+0.117
5Y1.1980.464+0.734
10Y2.2360.515+1.721
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Avalo Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Avalo Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -1.65 means the investor is paying $-1.65Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Avalo Therapeutics Inc:

  • The EOD is -0.984. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.649. Based on the earnings, the company is expensive. -2
  • The TTM is -0.190. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.984MRQ-1.649+0.665
MRQ-1.649TTM-0.190-1.459
TTM-0.190YOY-0.920+0.731
TTM-0.1905Y-0.338+0.149
5Y-0.33810Y-0.588+0.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.984-2.356+1.372
MRQ-1.649-2.077+0.428
TTM-0.190-2.574+2.384
YOY-0.920-3.760+2.840
3Y-0.322-3.773+3.451
5Y-0.338-6.193+5.855
10Y-0.588-6.876+6.288
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Avalo Therapeutics Inc:

  • The EOD is -1.368. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.293. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.983. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.368MRQ-2.293+0.925
MRQ-2.293TTM-1.983-0.309
TTM-1.983YOY-4.513+2.530
TTM-1.9835Y-1.594-0.389
5Y-1.59410Y-4.072+2.478
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.368-3.246+1.878
MRQ-2.293-2.705+0.412
TTM-1.983-3.704+1.721
YOY-4.513-4.402-0.111
3Y-2.366-5.070+2.704
5Y-1.594-8.477+6.883
10Y-4.072-9.305+5.233
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Avalo Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.71 means the investor is paying $0.71Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Avalo Therapeutics Inc:

  • The EOD is 0.422. Based on the equity, the company is cheap. +2
  • The MRQ is 0.707. Based on the equity, the company is cheap. +2
  • The TTM is -14.145. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.422MRQ0.707-0.285
MRQ0.707TTM-14.145+14.852
TTM-14.145YOY2.674-16.819
TTM-14.1455Y-3.247-10.898
5Y-3.24710Y1.960-5.207
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4222.038-1.616
MRQ0.7071.843-1.136
TTM-14.1452.125-16.270
YOY2.6742.442+0.232
3Y-6.0452.492-8.537
5Y-3.2473.652-6.899
10Y1.9604.311-2.351
4.6.2. Total Gains per Share

2.4. Latest News of Avalo Therapeutics Inc

Does Avalo Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Avalo Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-18
13:00
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of DirectorsRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Avalo Therapeutics Inc.

4.8.1. Institutions holding Avalo Therapeutics Inc

Institutions are holding 76.241% of the shares of Avalo Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Bvf Inc9.57440.3384103667900
2025-03-31Orbimed Advisors, LLC8.93090.184796700000
2025-03-31RA Capital Management, LLC8.93090.129496700000
2025-03-31Nantahala Capital Management, LLC8.31210.28659000009000000
2025-03-31Deep Track Capital, LP7.94150.223859876-7124-0.8217
2025-03-31Affinity Asset Advisors, LLC6.06920.502465715410638919.3166
2025-03-31Perceptive Advisors LLC4.80250.14685200005200000
2025-03-31COMMODORE CAPITAL LP4.46080.285148300000
2025-03-31TCG Crossover Management, LLC4.46080.527848300000
2025-03-31Adviser Investment Management Inc2.88870.03163127793127790
2025-03-31Ikarian Capital, LLC1.84710.1974200000-770259-79.3869
2025-03-31Vanguard Group Inc1.5418016694111400.6876
2025-03-31BlackRock Inc1.23501337264910.3685
2025-03-31Velan Capital Investment Management LP1.03410.922711197220001.8186
2025-03-31Geode Capital Management, LLC0.99570.000110781229592.822
2025-03-31Allostery Investments LP0.98951.23781071413382746.1399
2025-03-31UBS Group AG0.91390.0002989514320.4385
2025-03-31Sio Capital Management, LLC0.660.17057145800
2025-03-31Northern Trust Corp0.209402267300
2025-03-31Walleye Trading Advisors, LLC0.18680.0007202237463.8302
Total 75.98515.18518227385+1103380+13.4%

4.9.2. Funds holding Avalo Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.53130.000616580100
2025-04-30Fidelity Extended Market Index0.48420.000752431-501-0.9465
2025-03-31Extended Equity Market Fund K0.18040.001219533600.3081
2025-04-30Fidelity Total Market Index0.1720.00011862600
2025-04-30Fidelity Series Total Market Index0.12370.00011339900
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.10680.00151156500
2025-04-30Spartan Extended Market Index Pool F0.09940.0007107685014.8797
2025-03-31NT Ext Equity Mkt Idx Fd - L0.0980.00111061200
2025-03-31Northern Trust Extended Eq Market Idx0.0980.00111061200
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.08310.00169003-164-1.789
2025-04-30Fidelity Nasdaq Composite Index0.05730.0002620400
2025-04-30Spartan Total Market Index Pool G0.05680.0001615200
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.02350.00112549200.7908
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.02340.0009252925290
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.02340.0009252925290
2025-03-31Extended Equity Market Fund M0.02260.00122446-83-3.2819
2025-05-31State St US Ttl Mkt Indx NL Cl A0.0120.0001130400
2025-05-31Vanguard U.S. Eq Idx Β£ Acc0.01050114000
2025-03-31BNYM Mellon SL Market Completion UC10.01020.0021102-4-0.3617
2025-03-31Northern Trust Wilshire 50000.00460.000249600
Total 3.22120.0154348801+4887+1.4%

5.3. Insider Transactions

Insiders are holding 6.39% of the shares of Avalo Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-12June Sherie AlmenoffBUY50012.5
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets138,523
Total Liabilities15,908
Total Stockholder Equity122,615
 As reported
Total Liabilities 15,908
Total Stockholder Equity+ 122,615
Total Assets = 138,523

Assets

Total Assets138,523
Total Current Assets126,941
Long-term Assets11,582
Total Current Assets
Cash And Cash Equivalents 125,046
Other Current Assets 1,895
Total Current Assets  (as reported)126,941
Total Current Assets  (calculated)126,941
+/-0
Long-term Assets
Property Plant Equipment 949
Goodwill 10,502
Long-term Assets Other 131
Long-term Assets  (as reported)11,582
Long-term Assets  (calculated)11,582
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,615
Long-term Liabilities10,293
Total Stockholder Equity122,615
Total Current Liabilities
Accounts payable 681
Other Current Liabilities 4,253
Total Current Liabilities  (as reported)5,615
Total Current Liabilities  (calculated)4,934
+/- 681
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt801
Long-term Liabilities Other 2,000
Long-term Liabilities  (as reported)10,293
Long-term Liabilities  (calculated)2,801
+/- 7,492
Total Stockholder Equity
Common Stock11
Retained Earnings -383,412
Other Stockholders Equity 506,016
Total Stockholder Equity (as reported)122,615
Total Stockholder Equity (calculated)122,615
+/-0
Other
Capital Stock11
Cash and Short Term Investments 125,046
Common Stock Shares Outstanding 10,515
Liabilities and Stockholders Equity 138,523
Net Debt -125,046
Net Invested Capital 122,615
Net Working Capital 121,326



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312012-12-31
> Total Assets 
10,020
5,076
0
0
0
12,317
9,170
7,582
5,451
21,658
16,929
13,172
9,583
5,769
3,561
6,048
28,204
65,361
62,145
67,612
70,251
74,870
59,621
57,194
36,109
44,120
69,205
59,187
43,755
63,345
64,085
95,356
80,214
61,899
32,224
36,547
33,367
36,235
24,235
29,270
20,993
123,728
108,307
98,455
150,732
138,523
138,523150,73298,455108,307123,72820,99329,27024,23536,23533,36736,54732,22461,89980,21495,35664,08563,34543,75559,18769,20544,12036,10957,19459,62174,87070,25167,61262,14565,36128,2046,0483,5615,7699,58313,17216,92921,6585,4517,5829,17012,3170005,07610,020
   > Total Current Assets 
9,950
4,136
3,421
0
0
12,161
9,004
6,306
3,413
21,623
16,892
13,131
9,492
5,663
3,459
5,952
28,107
13,393
11,838
18,473
21,932
26,744
13,899
12,589
17,724
25,485
50,245
41,033
26,005
46,096
47,364
77,006
61,845
43,659
15,021
19,450
16,416
19,253
7,519
12,659
8,395
111,213
95,894
86,148
138,890
126,941
126,941138,89086,14895,894111,2138,39512,6597,51919,25316,41619,45015,02143,65961,84577,00647,36446,09626,00541,03350,24525,48517,72412,58913,89926,74421,93218,47311,83813,39328,1075,9523,4595,6639,49213,13116,89221,6233,4136,3069,00412,161003,4214,1369,950
       Cash And Cash Equivalents 
9,520
3,421
-3,421
0
0
11,742
8,599
6,143
3,308
21,162
16,602
11,880
8,815
5,128
3,002
5,461
23,955
2,524
2,180
6,838
10,646
16,121
9,387
5,251
3,609
5,659
45,391
33,391
18,919
38,292
40,435
71,506
54,585
38,469
11,249
16,943
13,172
16,687
6,307
10,180
7,416
110,181
93,426
81,858
134,546
125,046
125,046134,54681,85893,426110,1817,41610,1806,30716,68713,17216,94311,24938,46954,58571,50640,43538,29218,91933,39145,3915,6593,6095,2519,38716,12110,6466,8382,1802,52423,9555,4613,0025,1288,81511,88016,60221,1623,3086,1438,59911,74200-3,4213,4219,520
       Short-term Investments 
0
0
6,843
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,629
14,709
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000014,7097,6290000000000000000000006,84300
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
650
379
132
187
75
30
2,830
3,308
9,273
822
8,249
3,003
5,164
1,002
4,259
3,985
5,957
2,177
5,186
5,118
3,912
4,799
2,383
1,850
1,314
1,919
857
44
1,538
136
35
33
998
611
0
061199833351361,538448571,9191,3141,8502,3834,7993,9125,1185,1862,1775,9573,9854,2591,0025,1643,0038,2498229,2733,3082,830307518713237965000000000000
       Other Current Assets 
430
714
0
0
0
419
405
163
105
460
290
601
298
402
270
416
4,121
4,598
4,810
1,297
10,145
1,326
891
1,772
13,092
842
857
1,676
4,906
2,618
1,791
1,572
2,423
2,782
1,899
1,171
1,305
1,690
1,150
941
844
997
2,435
3,292
3,733
1,895
1,8953,7333,2922,4359978449411,1501,6901,3051,1711,8992,7822,4231,5721,7912,6184,9061,67685784213,0921,7728911,32610,1451,2974,8104,5984,121416270402298601290460105163405419000714430
   > Long-term Assets 
57
940
-3,421
0
0
156
166
1,277
2,038
35
37
41
90
106
102
96
97
51,968
50,307
49,139
48,319
48,126
45,722
44,605
18,385
18,634
18,960
18,154
17,750
17,249
16,721
18,350
18,369
18,240
17,203
17,097
16,951
16,982
16,716
16,611
12,598
12,515
12,413
12,307
11,842
11,582
11,58211,84212,30712,41312,51512,59816,61116,71616,98216,95117,09717,20318,24018,36918,35016,72117,24917,75018,15418,96018,63418,38544,60545,72248,12648,31949,13950,30751,9689796102106904137352,0381,27716615600-3,42194057
       Property Plant Equipment 
57
66
0
0
0
39
33
28
41
35
37
41
40
43
39
33
34
58
58
92
587
1,477
1,526
1,496
1,448
1,417
1,741
1,708
1,607
1,530
1,431
1,410
2,695
2,604
2,567
2,507
2,411
2,442
2,176
2,071
1,965
1,882
1,780
1,674
1,209
949
9491,2091,6741,7801,8821,9652,0712,1762,4422,4112,5072,5672,6042,6951,4101,4311,5301,6071,7081,7411,4171,4481,4961,5261,4775879258583433394340413735412833390006657
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,678
18,070
16,411
16,411
16,411
16,411
16,411
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
14,409
10,502
10,502
10,502
10,502
10,502
10,502
10,50210,50210,50210,50210,50210,50214,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40914,40916,41116,41116,41116,41116,41118,07018,67800000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,100
32,003
32,456
31,239
30,161
27,633
26,595
2,426
2,696
2,292
1,889
1,585
1,161
732
304
38
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000383047321,1611,5851,8892,2922,6962,42626,59527,63330,16131,23932,45632,00333,10000000000000000000
       Other Assets 
13
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149
149
149
149
2,227
1,227
1,227
227
181
131
0
131
0
0
0
0
0
0
0
000000013101311812271,2271,2272,2271491491491490000000000000000000000000013
> Total Liabilities 
1,544
3,066
0
0
0
38,648
38,688
9,906
38,302
8,574
8,048
7,601
8,996
5,562
3,987
2,912
6,083
40,778
42,926
48,104
49,343
51,750
41,925
38,973
15,113
18,531
18,627
20,620
19,194
30,190
42,497
55,047
57,132
55,556
38,175
38,575
44,282
42,502
31,204
14,575
13,689
224,813
110,458
77,379
17,700
15,908
15,90817,70077,379110,458224,81313,68914,57531,20442,50244,28238,57538,17555,55657,13255,04742,49730,19019,19420,62018,62718,53115,11338,97341,92551,75049,34348,10442,92640,7786,0832,9123,9875,5628,9967,6018,0488,57438,3029,90638,68838,6480003,0661,544
   > Total Current Liabilities 
1,544
3,066
0
0
0
4,994
5,751
5,812
6,654
5,850
6,172
6,586
7,496
4,312
2,737
1,662
4,833
14,789
19,045
24,912
26,217
28,135
18,765
17,262
12,160
15,330
14,595
16,571
15,225
26,360
21,674
19,038
19,888
17,893
15,395
18,149
22,114
23,245
22,454
6,005
4,618
215,700
96,397
60,674
6,960
5,615
5,6156,96060,67496,397215,7004,6186,00522,45423,24522,11418,14915,39517,89319,88819,03821,67426,36015,22516,57114,59515,33012,16017,26218,76528,13526,21724,91219,04514,7894,8331,6622,7374,3127,4966,5866,1725,8506,6545,8125,7514,9940003,0661,544
       Short-term Debt 
0
0
0
0
0
1,906
2,729
3,044
3,129
3,208
3,304
3,391
3,190
2,354
1,492
608
0
788
1,050
1,050
1,050
1,050
1,050
1,164
156
0
432
449
426
357
288
219
485
522
524
3,090
6,462
9,829
14,650
536
537
545
548
550
568
0
056855054854553753614,6509,8296,4623,09052452248521928835742644943201561,1641,0501,0501,0501,0501,05078806081,4922,3543,1903,3913,3043,2083,1293,0442,7291,90600000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,564
5,930
9,296
14,115
0
0
0
0
0
0
0
000000014,1159,2965,9302,56400000000000000000000000000000000000
       Accounts payable 
821
1,640
0
0
0
931
722
1,247
1,952
678
591
756
809
1,010
596
327
313
3,166
2,940
1,536
1,446
1,249
1,445
826
2,078
2,726
2,558
1,927
2,574
11,913
3,965
3,568
3,369
3,757
2,164
1,447
2,882
5,565
751
789
446
916
654
1,811
283
681
6812831,8116549164467897515,5652,8821,4472,1643,7573,3693,5683,96511,9132,5741,9272,5582,7262,0788261,4451,2491,4461,5362,9403,1663133275961,0108097565916781,9521,2477229310001,640821
       Other Current Liabilities 
723
1,426
0
0
0
2,157
2,300
1,522
1,574
1,964
2,277
2,438
3,497
948
648
727
1,291
8,569
12,884
20,131
21,688
24,021
14,877
14,257
9,375
12,604
11,606
14,196
12,225
14,090
17,421
15,251
16,034
13,614
12,707
13,170
12,682
7,740
7,053
4,680
3,635
214,239
95,195
58,313
6,453
4,253
4,2536,45358,31395,195214,2393,6354,6807,0537,74012,68213,17012,70713,61416,03415,25117,42114,09012,22514,19611,60612,6049,37514,25714,87724,02121,68820,13112,8848,5691,2917276489483,4972,4382,2771,9641,5741,5222,3002,1570001,426723
   > Long-term Liabilities 
0
0
0
0
0
33,654
32,937
4,094
31,648
8,574
1,876
1,015
1,500
1,250
1,250
1,250
1,250
25,989
23,880
23,193
23,126
23,615
23,160
21,710
2,953
3,201
4,032
4,049
3,969
3,830
20,823
36,009
37,244
37,663
22,780
20,426
22,168
19,257
8,750
8,570
9,071
9,113
14,061
16,705
10,740
10,293
10,29310,74016,70514,0619,1139,0718,5708,75019,25722,16820,42622,78037,66337,24436,00920,8233,8303,9694,0494,0323,2012,95321,71023,16023,61523,12623,19323,88025,9891,2501,2501,2501,2501,5001,0151,8768,57431,6484,09432,93733,65400000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,143
32,483
0
0
0
0
0
10,470
0
0
0
0
0
0
0
0
0000000010,4700000032,48317,143000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,955
2,930
2,812
2,682
3,526
4,411
2,535
4,067
3,924
6,971
0
8,750
0
0
0
0
0
0
0
00000008,75006,9713,9244,0672,5354,4113,5262,6822,8122,9302,955000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90
111
122
130
0
0
0
0
0
5,158
0
0
0
0
0
0
0
0
000000005,15800000130122111900000000000000000000000000000
> Total Stockholder Equity
8,476
2,010
2,010
0
0
-26,331
-29,518
-2,324
-32,851
13,084
8,881
5,571
587
207
-426
3,135
22,120
24,583
19,219
19,508
20,908
23,121
17,696
18,221
20,996
25,589
50,578
38,567
24,562
33,155
21,588
40,309
23,082
6,343
-5,951
-2,028
-10,915
-6,267
-6,969
14,695
7,304
-101,085
-2,151
21,076
133,032
122,615
122,615133,03221,076-2,151-101,0857,30414,695-6,969-6,267-10,915-2,028-5,9516,34323,08240,30921,58833,15524,56238,56750,57825,58920,99618,22117,69623,12120,90819,50819,21924,58322,1203,135-4262075875,5718,88113,084-32,851-2,324-29,518-26,331002,0102,0108,476
   Common Stock
18
18
0
0
0
1
18
5
1
9
9
9
9
9
11
14
26
2,687
34
41
41
43
43
44
44
60
75
75
75
89
96
112
113
113
9
9
9
13
14
192
1
1
1
10
10
11
1110101111921413999113113112968975757560444443434141342,68726141199999151810001818
   Retained Earnings Total Equity00000000-313,77900000-242,970-225,575-208,470-177,7900000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-17,847
0
0
-28,346
0
-28,346
0
0
0
0
0
0
0
0
0
2,655
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-11,457
-11,457
-1,658
0
0
00-1,658-11,457-11,457000000000000000000000002,655000000000-28,3460-28,34600-17,84700
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
202,276
241,535
247,067
283,167
0
0
0
0
0
307,499
0
0
0
0
0
0
0
0
00000000307,49900000283,167247,067241,535202,2760000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
2,574
9,153
0
0
0
-11,603
16,775
75,245
17,063
66,639
67,576
67,790
68,974
70,233
71,559
76,916
77,168
86,600
87,241
112,126
119,082
128,747
129,546
134,086
135,239
160,936
199,191
200,639
202,274
241,535
247,067
283,167
285,135
290,447
291,244
291,975
292,900
307,499
314,755
341,469
342,437
355,338
355,809
354,332
503,285
506,016
506,016503,285354,332355,809355,338342,437341,469314,755307,499292,900291,975291,244290,447285,135283,167247,067241,535202,274200,639199,191160,936135,239134,086129,546128,747119,082112,12687,24186,60077,16876,91671,55970,23368,97467,79067,57666,63917,06375,24516,775-11,6030009,1532,574



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue441
Cost of Revenue--366
Gross Profit807807
 
Operating Income (+$)
Gross Profit807
Operating Expense-69,319
Operating Income-68,512-68,512
 
Operating Expense (+$)
Research Development52,078
Selling General Administrative16,452
Selling And Marketing Expenses789
Operating Expense69,31969,319
 
Net Interest Income (+$)
Interest Income0
Interest Expense-3,317
Other Finance Cost-6,634
Net Interest Income3,317
 
Pretax Income (+$)
Operating Income-68,512
Net Interest Income3,317
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,015-102,009
EBIT - interestExpense = -71,829
-35,015
-31,812
Interest Expense3,317
Earnings Before Interest and Taxes (EBIT)-68,512-31,698
Earnings Before Interest and Taxes (EBITDA)-68,343
 
After tax Income (+$)
Income Before Tax-35,015
Tax Provision-114
Net Income From Continuing Ops-35,129-35,129
Net Income-35,129
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,953
Total Other Income/Expenses Net33,497-3,317
 

Technical Analysis of Avalo Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Avalo Therapeutics Inc. The general trend of Avalo Therapeutics Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Avalo Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Avalo Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Avalo Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.05 < 5.47 < 5.99.

The bearish price targets are: 4.46 > 3.4313 > 3.39.

Know someone who trades $AVTX? Share this with them.πŸ‘‡

Avalo Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Avalo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Avalo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Avalo Therapeutics Inc. The current macd is 0.09738771.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avalo Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Avalo Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Avalo Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Avalo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAvalo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Avalo Therapeutics Inc. The current adx is 12.78.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Avalo Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Avalo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Avalo Therapeutics Inc. The current sar is 5.02532416.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Avalo Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Avalo Therapeutics Inc. The current rsi is 51.36. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Avalo Therapeutics Inc Daily Relative Strength Index (RSI) ChartAvalo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Avalo Therapeutics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avalo Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Avalo Therapeutics Inc Daily Stochastic Oscillator ChartAvalo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Avalo Therapeutics Inc. The current cci is -32.4796666.

Avalo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAvalo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Avalo Therapeutics Inc. The current cmo is -1.28338644.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Avalo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAvalo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Avalo Therapeutics Inc. The current willr is -49.09090909.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Avalo Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Avalo Therapeutics Inc Daily Williams %R ChartAvalo Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Avalo Therapeutics Inc.

Avalo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Avalo Therapeutics Inc. The current atr is 0.3099838.

Avalo Therapeutics Inc Daily Average True Range (ATR) ChartAvalo Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Avalo Therapeutics Inc. The current obv is 33,961,174.

Avalo Therapeutics Inc Daily On-Balance Volume (OBV) ChartAvalo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Avalo Therapeutics Inc. The current mfi is 65.40.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Avalo Therapeutics Inc Daily Money Flow Index (MFI) ChartAvalo Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Avalo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Avalo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Avalo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.365
Ma 20Greater thanMa 504.812
Ma 50Greater thanMa 1004.462
Ma 100Greater thanMa 2005.566
OpenGreater thanClose4.880
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Avalo Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Avalo Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Avalo Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Avalo Therapeutics Inc

I send you an email if I find something interesting about Avalo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Avalo Therapeutics Inc.

Receive notifications about Avalo Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.